Cure and care for children and adolescents with acute myeloid leukemia in Middle and Eastern European countries: part II

Dworzak, Michael

doi:10.1007/s12254-014-0134-z

Cited by 2 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…10 However some of the most important chemotherapeutics used in the AML-BFM backbone today are still not licensed for the treatment of children and adolescents in Europe and are currently being used on an off-label basis. 13 The OS and EFS rates of children with AML we report are largely due to the use of a unifi ed treatment strategy, using a single treatment protocol. In all of the 3 Bulgarian pediatric oncohematology centers standardized risk group assignment is applied, with timely HLA-typing and referral for transplantation for the HR patients.…”

Section: Resultsmentioning

confidence: 91%

Treatment of Childhood Acute Myeloid Leukemia in Bulgaria

Burnusuzov

Yordanova²,

Avramova³

et al. 2018

Folia Medica

View full text Add to dashboard Cite

Background: During the last four decades the prognosis of childhood acute myeloid leukemia (AML) has been substantially improved due to an increase in complete remission (CR) rates, event-free survival (EFS) and reduced early mortality. The relapsed AML still remains a therapeutic challenge. Aim: To report the AML treatment results of the Bulgarian pediatric oncohematological centers. Materials and methods: Retrospective analysis of the treatment results of children and adolescents (age from 0 to 20 years) with primary AML. Unifi ed AML BFM-backbone type treatment protocol is used. Results: This study included 97 newly diagnosed patients (44 girls and 53 boys) with AML in Bulgaria between 2003 and 2016. The median age at diagnosis was 10.2 years. The most frequent FAB-morphologic subtype was М2 followed by М4. First complete remission (CR1) was achieved in 83 patients (85.6%). The 13-year EFS was 49%, while the overall survival (OS) was 54.6%. Twenty seven (27.8%) patients relapsed, with only 5 of them being still alive towards the end of the study period. Conclusion: The EFS and OS for the children with AML in Bulgaria are comparable with those reported by other European groups. The prognosis of relapsed AML remains still unfavorable for the past 13 years. BACKGROUND

show abstract

Section: Resultsmentioning

confidence: 91%